RIPK1-IN-19

RIPK1-IN-19 is a selective RIPK1 inhibitor (IC50=15 nM) . RIPK1-IN-19 does not show obvious activity against RIPK2, RIPK3, and RIPK4. RIPK1-IN-19 displays potent protective activity in TNFα-induced systemic inflammatory response syndrome (SIRS) model and Imiquimod (IMQ) -induced psoriasis model. RIPK1-IN-19 can be used in research on inflammation and immune system diseases[1].

Product Specifications

CAS Number

[2763831-43-0]

UNSPSC

12352005

Target

RIP kinase

Type

Reference compound

Related Pathways

Apoptosis

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/ripk1-in-19.html

Purity

98.87

Solubility

10 mM in DMSO

Smiles

C[C@@H](C1=CC=CC(F)=C1)NC(C2=CN(C3=C2C=C(C=C3)C4=CC5=NC(NC(C6CC6)=O)=NN5C=C4)C)=O

Molecular Formula

C28H25FN6O2

Molecular Weight

496.54

References & Citations

[1]Zhang L, et al. From Hit to Lead: Structure-Based Optimization of Novel Selective Inhibitors of Receptor-Interacting Protein Kinase 1 (RIPK1) for the Treatment of Inflammatory Diseases. J Med Chem. 2024 Jan 11;67 (1) :754-773.